Organovo Holdings, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
VivoSim Labs, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 9,411,766 shares of common stock.
VivoSim Labs, Inc. files an S-1/A for a best efforts public offering of up to $4 million in common stock and warrants, aiming to fund operations through 2027 despite significant accumulated losses and auditor's going concern warning.
VivoSim Labs, a biotech services firm, is conducting a best efforts public offering of up to $4 million in common stock and warrants to fund operations, despite an auditor's 'going concern' warning and significant accumulated losses.
Organovo Holdings, Inc. plans to raise capital through a public offering of common stock and warrants to advance its FXR314 clinical program and 3D tissue development efforts.
Organovo Holdings seeks to raise capital through a public offering to fund the clinical development of FXR314 for inflammatory bowel disease and further its 3D tissue technology.
Organovo Holdings seeks to raise up to $10 million through a common stock and pre-funded warrant offering to fund working capital and advance its FXR314 program for inflammatory bowel disease.